<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471260</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0490</org_study_id>
    <secondary_id>NCI-2018-00921</secondary_id>
    <secondary_id>2017-0490</secondary_id>
    <nct_id>NCT03471260</nct_id>
  </id_info>
  <brief_title>Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies</brief_title>
  <official_title>Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it&#xD;
      works when given together with ivosidenib with or without azacitidine, in treating patients&#xD;
      with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of&#xD;
      cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in&#xD;
      chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells,&#xD;
      either by killing the cells, by stopping them from dividing, or by stopping them from&#xD;
      spreading. Giving ivosidenib and venetoclax with azacitidine may work better in treating&#xD;
      patients with hematologic malignancies compared to ivosidenib and venetoclax alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety and tolerability, maximum tolerated dose (MTD), and recommended&#xD;
      phase 2 dose (RP2D) of the combination of ivosidenib with venetoclax, with or without the&#xD;
      addition of azacitidine, in IDH1-mutated patients with advanced hematologic malignancies.&#xD;
      (Phase Ib) II. To determine the overall response rate (ORR) including complete response (CR),&#xD;
      CR with incomplete blood count recovery (CRi), morphologic leukemia-free state (MLFS), and&#xD;
      partial response (PR) of the combination of ivosidenib and venetoclax, with or without the&#xD;
      addition of azacitidine, in IDH1-mutated patients with acute myeloid leukemia (AML). (Phase&#xD;
      II)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Characterize the pharmacokinetic (PK) profiles of venetoclax and ivosidenib in combination&#xD;
      in plasma samples (in Part 1b).&#xD;
&#xD;
      II. To evaluate molecular and cellular biomarkers that may be predictive of antitumor&#xD;
      activity and/or resistance to treatment including evaluation of 2HG, IDH1 VAF levels before,&#xD;
      during and after treatment.&#xD;
&#xD;
      III. To determine time to event endpoints including duration of response (DOR), event free&#xD;
      survival (EFS) and overall survival (OS).&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate minimal residual disease (MRD) using multiparameter flow cytometry, cytogenetics&#xD;
      and molecular evaluation.&#xD;
&#xD;
      II. Evaluate global gene expression profiles, deoxyribonucleic acid (DNA) methylation&#xD;
      profiles, BH3 profiling and other potential prognostic markers to explore predictors of&#xD;
      antitumor activity and/or resistance to treatment.&#xD;
&#xD;
      OUTLINE: This is a phase Ib, dose-escalation study of venetoclax followed by a phase II&#xD;
      study.&#xD;
&#xD;
      Patients receive venetoclax orally (PO) daily on days 1-14. Patients also receive ivosidenib&#xD;
      PO daily on days 15-28 of cycle 1 and days 1-28 of subsequent cycles. Patients may also&#xD;
      receive azacitidine intravenously (IV) over 30-60 minutes or subcutaneously (SC) on days 1-7.&#xD;
      Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days, and then monthly&#xD;
      for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Defined as complete response (CR), CR with incomplete blood count recovery (CRi), morphologic leukemia-free state (MLFS), and partial response (PR) based on revised International Working Group (IWG) response criteria. Analysis will be performed for enrolled subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be collected using leukemia adverse event guidelines.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>Defined as any grade 3 or 4, clinically significant non-hematologic adverse event or abnormal laboratory value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to therapy</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From the date of initial response to first documented disease progression/relapse or death, assessed up to 3 years</time_frame>
    <description>Will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>From treatment initiation to date of documented treatment failure, relapse, or death from any cause, assessed up to 3 years</time_frame>
    <description>Will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be calculated.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma concentrations and pharmacokinetic parameter</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be tabulated for each subject, visit, and dose level, and summary statistics will be computed for each sampling time and each parameter.</description>
  </other_outcome>
  <other_outcome>
    <measure>Peripheral blood and bone marrow aspirate samples</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Biomarker assays may include, but are not limited to, BH3 profiling and characterization of BCL-2 and related proteins, IDH1 mutant status, serum R-2HG analysis, and assessment of the depth of response and monitoring of disease recurrence by assessment of minimal residual disease in the bone marrow.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Hematopoietic and Lymphoid System Neoplasm</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (venetoclax, ivosidenib, azacitidine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive venetoclax PO daily on days 1-14. Patients also receive ivosidenib PO daily on days 15-28 of cycle 1 and days 1-28 of subsequent cycles. Patients may also receive azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Given IV or SC</description>
    <arm_group_label>Treatment (venetoclax, ivosidenib, azacitidine)</arm_group_label>
    <other_name>5 AZC</other_name>
    <other_name>5-AC</other_name>
    <other_name>5-Azacytidine</other_name>
    <other_name>5-AZC</other_name>
    <other_name>Azacytidine</other_name>
    <other_name>Azacytidine, 5-</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>Mylosar</other_name>
    <other_name>Onureg</other_name>
    <other_name>U-18496</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivosidenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (venetoclax, ivosidenib, azacitidine)</arm_group_label>
    <other_name>AG-120</other_name>
    <other_name>Tibsovo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (venetoclax, ivosidenib, azacitidine)</arm_group_label>
    <other_name>ABT-0199</other_name>
    <other_name>ABT-199</other_name>
    <other_name>ABT199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>RG7601</other_name>
    <other_name>Venclexta</other_name>
    <other_name>Venclyxto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of =&lt; 2.&#xD;
&#xD;
          -  IDH1-R132 mutated disease status as assessed by local laboratory. 2HG-producing IDH1&#xD;
             variants outside of R132 (i.e. R100) may be eligible after discussion with the&#xD;
             principal investigator (PI).&#xD;
&#xD;
          -  Relapsed/refractory AML, or treatment-naive patients with AML who are not eligible for&#xD;
             standard induction chemotherapy. Patients with high-risk myelodysplastic syndrome&#xD;
             (MDS) or myeloproliferative neoplasm (MPN) (defined as &gt;= 10% bone marrow blasts, or&#xD;
             intermediate or high risk by International Prostate Symptom Score [IPSS], Revised&#xD;
             [R]-IPSS or Dynamic [D]-IPSS) may also be eligible after discussion with the PI&#xD;
&#xD;
          -  Direct bilirubin =&lt; 2 x upper limit of normal (ULN) unless deemed to be related to&#xD;
             underlying leukemia.&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =&lt; 3 x ULN&#xD;
             unless deemed to be related to underlying leukemia.&#xD;
&#xD;
          -  Creatinine clearance &gt;= 30 ml/min based on the Cockcroft-Gault equation.&#xD;
&#xD;
          -  Willing and able to provide informed consent.&#xD;
&#xD;
          -  In the absence of rapidly proliferative disease, the interval from prior treatment to&#xD;
             time of initiation will be at least 7 days for cytotoxic or non-cytotoxic&#xD;
             (immunotherapy) agents.&#xD;
&#xD;
          -  Male subjects must agree to refrain from unprotected sex and sperm donation from&#xD;
             initial study drug administration until 90 days after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known allergy or hypersensitivity to ivosidenib or venetoclax.&#xD;
&#xD;
          -  Patients who have previously received either ivosidenib or venetoclax.&#xD;
&#xD;
          -  Patients with any concurrent uncontrolled clinically significant medical condition&#xD;
             including infection, laboratory abnormality, or psychiatric illness, which could place&#xD;
             the patient at unacceptable risk of study treatment&#xD;
&#xD;
          -  The use of other chemotherapeutic agents or anti-leukemic agents is not permitted&#xD;
             during study with the following exceptions (1) intrathecal chemotherapy for&#xD;
             prophylactic use or for controlled central nervous system (CNS) leukemia. (2) use of&#xD;
             hydroxyurea and/or one dose of cytarabine (up to 2 g/m^2) for patients with rapidly&#xD;
             proliferative disease is allowed before the start of study therapy and for the first&#xD;
             four weeks on therapy.&#xD;
&#xD;
          -  Patients receiving concomitant treatment with strong CYP3A4 inhibitors within 3 days&#xD;
             of start of study therapy (including posaconazole and voriconazole).&#xD;
&#xD;
          -  Patients receiving concomitant strong CYP3A inducers (avasimibe, carbamazepine,&#xD;
             phenytoin, rifampin, rifabutin, St. John's wort) within 3 days of start of study&#xD;
             therapy.&#xD;
&#xD;
          -  Patients with active graft-versus-host-disease (GVHD) status post stem cell transplant&#xD;
             (patients without active GVHD on chronic suppressive immunosuppression and/or&#xD;
             phototherapy for chronic skin GVHD are permitted after discussion with the PI).&#xD;
&#xD;
          -  Patients with any severe gastrointestinal or metabolic condition which could interfere&#xD;
             with the absorption of oral study medications.&#xD;
&#xD;
          -  Patients with a concurrent active malignancy under treatment.&#xD;
&#xD;
          -  Corrected QT (QTc) interval using Fridericia's formula (QTcF) &gt;= 450 msec. Bundle&#xD;
             branch block and prolonged QTc interval are permitted after discussion with the PI.&#xD;
&#xD;
          -  Known active hepatitis B (HBV) or hepatitis C (HCV) infection or known human&#xD;
             immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  Subject has a white blood cell count &gt; 25 x 10^9/L. (Note: Hydroxyurea is permitted to&#xD;
             meet this criterion.)&#xD;
&#xD;
          -  Nursing women, women of childbearing potential (WOCBP) with positive urine pregnancy&#xD;
             test, or women of childbearing potential who are not willing to maintain adequate&#xD;
             contraception.&#xD;
&#xD;
               -  Appropriate highly effective method(s) of contraception include oral or&#xD;
                  injectable hormonal birth control, intrauterine device (IUD), and double barrier&#xD;
                  methods (for example a condom in combination with a spermicide).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Courtney DiNardo</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Courtney DiNardo</last_name>
    <phone>713-794-1141</phone>
    <email>cdinardo@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline S. Garcia</last_name>
      <phone>617-632-2168</phone>
      <email>Jacqueline_Garcia@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Jacqueline S. Garcia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eunice S. Wang</last_name>
      <phone>716-845-2300</phone>
      <email>eunice.wang@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Eunice S. Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>bhumika patel</last_name>
      <phone>216-444-8665</phone>
      <email>patelb3@ccf.org</email>
    </contact>
    <investigator>
      <last_name>bhumika patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney DiNardo</last_name>
      <phone>713-794-1141</phone>
      <email>cdinardo@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Courtney DiNardo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Ivosidenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

